Eight posters including one oral presentation support ongoing research and clinical experience with Hizentra®, the first and only subcutaneous immunoglobulin (Ig) therapy approved to address the unique needs of CIDP patients. Presentations include new analysis from...
– AB-729 is a subcutaneously-administered RNAi agent targeting HBV replication and HBsAg antigen production – Supports corporate objective to combine AB-729 with AB-506, Arbutus’ proprietary oral capsid inhibitor WARMINSTER, Pa., June 20, 2019 (GLOBE...
Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug...
Cancer Prevention Pharmaceuticals, Inc. (CPP) recently reported results from its pivotal Phase 3 trial of CPP-1X/sul for adults with familial adenomatous polyposis (FAP) at the Digestive Disease Week annual conference in San Diego. FAP is a rare genetic disease that...
Today Florence announced assignment of U.S. Patent No. 10,319,479 by the United States Patent and Trademark Office for: “Remote Monitoring and Dynamic Document Management Systems and Methods.” This patent covers how Florence’s applications process...
Email
Text